LN-145 (TIL therapy)

About Iovance Biotherapeutics

Iovance Biotherapeutics aims to be the global leader in developing and delivering TIL therapy for cancer patients. The company has achieved a landmark with the first FDA approval of a TIL therapy (Amtagvi/lifileucel) for advanced melanoma and is rapidly expanding into other solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, and endometrial cancer. With a state-of-the-art manufacturing facility and multiple ongoing clinical trials, Iovance is positioned to transform cancer treatment through its personalized cell therapy platform.

Therapeutic Areas